Such discrepancies can be explained by the cancer type, the in situ location (peritumoral, intratumoral, or stromal) of neutrophils but also by differences in staining methods such as haematoxylin/eosin (HE), neutrophil elastase (NE), Arginase, MPO, CD66b, or CD15 surface markers. This evidence concerns the gene CEACAM8 and cancer.